Protara Therapeutics Inc is a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. The company focuses on developing novel therapeutic candidates derived from established mechanisms to create new development opportunities. Its core activities involve research, preclinical development, and clinical testing of product candidates to address significant unmet medical needs in oncology and rare disease populations.

Protara Therapeutics Inc does not currently generate revenue from product sales as it has no approved products on the market. The company’s financial resources are derived from capital raising activities including private placements, public offerings, and the exercise of warrants. It relies on external financing to fund its research and development programs and general and administrative operations.

The company operates through the following segments: TARA-002 in non-muscle invasive bladder cancer, TARA-002 in lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support.

• TARA-002 in non-muscle invasive bladder cancer is an investigational cell therapy based on the immunopotentiator OK-432, being evaluated for the treatment of high-grade carcinoma in situ, with ongoing Phase 2 clinical trials including the ADVANCED-2 study assessing safety and efficacy in BCG-naïve and BCG-unresponsive patient populations.

• TARA-002 in lymphatic malformations is an investigational cell therapy being studied for the treatment of macrocystic and mixed-cystic lymphatic malformations in pediatric patients, utilizing intracystic injection in the STARBORN-1 Phase 2 clinical trial to evaluate clinical success based on volumetric reduction measured by axial imaging.

• IV Choline Chloride is an investigational phospholipid substrate replacement therapy developed for patients receiving parenteral support who cannot obtain sufficient choline from enteral nutrition, with ongoing clinical development including the THRIVE-3 Phase 2b/3 trial designed to assess efficacy and safety in restoring plasma choline levels over 24 weeks in adolescents and adults on long-term parenteral nutrition when oral or enteral intake is not possible.

Protara Therapeutics Inc operates in the competitive biopharmaceutical industry focused on innovative therapies for bladder cancer, rare pediatric diseases, and nutritional deficiencies in parenteral support patients. The company differentiates itself through its proprietary TARA-002 platform derived from OK-432, its orphan drug and rare pediatric disease designations, and its focus on addressing underserved patient populations with limited treatment options, supported by clinical data demonstrating encouraging response rates in early-stage trials.

The company serves patients with high-grade non-muscle invasive bladder cancer, children and adolescents with lymphatic malformations, and adults and adolescents dependent on long-term parenteral support who are at risk of choline deficiency, including those receiving home parenteral nutrition due to intestinal failure or other medical conditions preventing adequate oral or enteral nutrient intake.